Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule Of Components Of (Loss) Income Before Income Tax

The components of (loss) income before income taxes for the years ended twelve months ended December 31, are as follows: 

(Loss) Income Before Income Taxes:	2022		2021
Ireland	$	(53,717)	$	(36,631)
U.S.	(57,755)		(56,687)
France	33		173
Total loss before income taxes	$	(111,439)	$	(93,145)

Schedule Of Income Tax Provision (Benefit)

The income tax provision (benefit) consists of the following for the years ended December 31:  

Income Tax Provision (Benefit):	2022		2021
Current:
U.S. - State	$	—	$	60
Total current	—		60
Deferred:
U.S. - Federal	25,896		(15,876)
U.S. - State	129		—
Total deferred	26,025		(15,876)
Income tax provision (benefit)	$	26,025	$	(15,816)

Schedule of Effective Income Tax Rate Reconciliation

The reconciliation between income taxes at the statutory rate and the Company’s provision (benefit) for income taxes is as follows for the years ended December 31: 

Reconciliation to Effective Income Tax Rate:	2022		2021
Income tax provision (benefit) - at statutory tax rate	$	(13,916)	$	(11,642)
Differences in international tax rates	(9,921)		(8,950)
Change in valuation allowances	48,734		4,296
Nondeductible share-based compensation	1,424		645
Unrealized tax benefits	258		239
State and local taxes (net of federal)	(4,467)		60
Nondeductible interest expense	4,239		2,173
Orphan drug and R&D tax credit	—		(1,524)
Other	(326)		(1,113)
Income tax provision (benefit) - at effective income tax rate	$	26,025	$	(15,816)

Summary of Unrecognized Tax Benefits

The following table summarizes the activity related to the Company’s unrecognized tax benefits for the twelve months ended December 31:

Unrecognized Tax Benefit Activity	2022		2021
Balance at January 1:	$	3,143	$	3,143
Increases for tax positions of prior years	—		—
Statute of limitations expiration	—		—
Settlements	—		—
Balance at December 31:	$	3,143	$	3,143

Schedule of Deferred Tax Assets and Liabilities

The net deferred tax assets (liabilities) at December 31, 2022 and 2021 resulted from the following temporary differences: 

Net Deferred Tax Assets and Liabilities:	2022		2021
Deferred tax assets:
Net operating loss carryforwards	$	53,393	$	34,399
Share-based compensation	4,684		4,108
Amortization	3,541		3,429
Orphan drug and R&D tax credit	4,964		4,964
Capitalized research costs	2,108		—
Other	1,521		662
Interest expense carryforward	1,216		1,591
Gross deferred tax assets	71,427		49,153
Deferred tax liabilities:
Prepaid expenses	(86)		(75)
Other	—		(925)
Gross deferred tax liabilities	(86)		(1,000)
Less: valuation allowances	(71,341)		(24,025)
Net deferred tax assets	$	—	$	24,128